Literature DB >> 30521105

A randomized, double-blind, placebo-controlled trial of probiotics to reduce the severity of oral mucositis induced by chemoradiotherapy for patients with nasopharyngeal carcinoma.

Chunling Jiang1,2, Huan Wang3, Chaofei Xia3, Qing Dong1, En Chen1, Yang Qiu1, Yong Su1, Honghui Xie1, Lei Zeng1, Jie Kuang4, Fan Ao1, Xiaochang Gong1, Jingao Li1,2, Tingtao Chen3.   

Abstract

BACKGROUND: The objective of this study was to evaluate the effect of a probiotic combination on the severity of oral mucositis (OM), which is a common, unpreventable complication induced by radiochemotherapy in patients with nasopharyngeal carcinoma who undergo concurrent radiochemotherapy (CCRT).
METHODS: Eligible patients (n = 99) with locally advanced nasopharyngeal carcinoma who were undergoing CCRT were randomly assigned (2:1) to receive a probiotic combination or placebo during radiochemotherapy, and the incidence of severe OM (grade 3 or higher) was the primary endpoint.
RESULTS: Patients taking the probiotic combination showed a significant reduction in the severity of OM. The incidences of grade 0, 1, 2, and 3 OM in the placebo group and the probiotic combination group were 0% and 12.07%, 0% and 55.17%, 54.29% and 17.24%, and 45.71% and 15.52%, respectively. Furthermore, CCRT greatly lowered the number of immune cells, whereas the probiotic combination markedly lowered the reduction rates of CD4+ T cells (76.59% vs 52.85%; P < .05), CD8+ T cells (62.94% vs 29.76%; P < .05), and CD3+ T cells (69.72% vs 45.49%; P < .05) in an A-CCRT-P (after treatment with radiotherapy plus chemotherapy plus the probiotic combination) group. High-throughput sequencing results indicated that CCRT had obviously disturbed the intestinal diversity of patients in an A-CCRT (after treatment with radiotherapy plus chemotherapy plus a placebo) group, whereas the probiotic combination distinctly restored the microbial diversity in the A-CCRT-P group toward that of healthy people and a B-CCRT-P (before the treatment of radiotherapy plus chemotherapy plus the probiotic combination) group.
CONCLUSIONS: A probiotic combination significantly enhances the immune response of patients and reduces the severity of OM through modification of gut microbiota.
© 2018 American Cancer Society.

Entities:  

Keywords:  concurrent radiochemotherapy; microbial diversity; nasopharyngeal carcinoma; oral mucositis; probiotics

Mesh:

Substances:

Year:  2018        PMID: 30521105     DOI: 10.1002/cncr.31907

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  23 in total

Review 1.  Influence of Probiotics in Prevention and Treatment of Patients Who Undergo Chemotherapy or/and Radiotherapy and Suffer from Mucositis, Diarrhoea, Constipation, Nausea and Vomiting.

Authors:  Aleksandra Garczyk; Iwona Kaliciak; Konstanty Drogowski; Paulina Horwat; Stanisław Kopeć; Zuzanna Staręga; Paweł Bogdański; Marta Stelmach-Mardas; Marcin Mardas
Journal:  J Clin Med       Date:  2022-06-14       Impact factor: 4.964

2.  Commensal oral microbiota impacts ulcerative oral mucositis clinical course in allogeneic stem cell transplant recipients.

Authors:  Julia S Bruno; Vitor Heidrich; Franciele H Knebel; Vinícius Campos de Molla; Claudia Joffily Parahyba; Wanessa Miranda-Silva; Paula F Asprino; Luciana Tucunduva; Vanderson Rocha; Yana Novis; Celso Arrais-Rodrigues; Anamaria A Camargo; Eduardo R Fregnani
Journal:  Sci Rep       Date:  2022-10-20       Impact factor: 4.996

Review 3.  Challenges in the production and use of probiotics as therapeuticals in cancer treatment or prevention.

Authors:  Alejandra Mejía-Caballero; Vianey Anahi Salas-Villagrán; Alaide Jiménez-Serna; Amelia Farrés
Journal:  J Ind Microbiol Biotechnol       Date:  2021-12-23       Impact factor: 4.258

Review 4.  Review of probiotic use in otolaryngology.

Authors:  Alexandra T Bourdillon; Heather A Edwards
Journal:  Am J Otolaryngol       Date:  2021-01-05       Impact factor: 2.873

Review 5.  Novel cancer therapy targeting microbiome.

Authors:  Tatsuya Nagano; Takehiro Otoshi; Daisuke Hazama; Tatsunori Kiriu; Kanoko Umezawa; Naoko Katsurada; Yoshihiro Nishimura
Journal:  Onco Targets Ther       Date:  2019-05-13       Impact factor: 4.147

Review 6.  Intestinal Microbiota: A Novel Target to Improve Anti-Tumor Treatment?

Authors:  Romain Villéger; Amélie Lopès; Guillaume Carrier; Julie Veziant; Elisabeth Billard; Nicolas Barnich; Johan Gagnière; Emilie Vazeille; Mathilde Bonnet
Journal:  Int J Mol Sci       Date:  2019-09-17       Impact factor: 5.923

7.  Chemotherapy-induced neuroinflammation is associated with disrupted colonic and bacterial homeostasis in female mice.

Authors:  B R Loman; K R Jordan; B Haynes; M T Bailey; L M Pyter
Journal:  Sci Rep       Date:  2019-11-11       Impact factor: 4.379

8.  Search and Selection of Probiotics That Improve Mucositis Symptoms in Oncologic Patients. A Systematic Review.

Authors:  José Antonio Picó-Monllor; José Manuel Mingot-Ascencao
Journal:  Nutrients       Date:  2019-10-01       Impact factor: 5.717

9.  Intestinal Flora Disruption and Novel Biomarkers Associated With Nasopharyngeal Carcinoma.

Authors:  Haiye Jiang; Jian Li; Bin Zhang; Rong Huang; Junhua Zhang; Ziwei Chen; Xueling Shang; Xisheng Li; Xinmin Nie
Journal:  Front Oncol       Date:  2019-12-06       Impact factor: 6.244

10.  Intestinal microbiota regulates anti-tumor effect of disulfiram combined with Cu2+ in a mice model.

Authors:  Hong Hu; Lanyue Cui; Jiachen Lu; Kehong Wei; Jing Wei; Shaobo Li; Changwei Zou; Tingtao Chen
Journal:  Cancer Med       Date:  2020-08-04       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.